Praluent Cost in California 2026: Prices, Coverage, and How to Pay Less

What Is the Cash Price for Praluent in California in 2026?

The retail cash price for Praluent in California sits at roughly $580 per month in 2026, consistent with the manufacturer's published list price. That figure applies whether you fill at a large chain pharmacy or an independent California retail pharmacy. No significant regional variation exists within the state because Regeneron and Sanofi set a single wholesale acquisition cost nationally.

For context, $580/month equals roughly $6,960 per year at list price. That number looks steep but rarely reflects what insured patients or savings-card users actually pay. The gap between list price and net price has been a persistent feature of the PCSK9 inhibitor market since Praluent received FDA approval in July 2015. Praluent FDA label and approval history

Two factors drive actual out-of-pocket cost more than list price: whether a patient has qualifying insurance and whether they use the manufacturer savings program. Sections below break down both paths.

Why Cash Price Matters Even With Insurance

Some California patients face situations where cash-pay pricing is relevant. High-deductible health plans (HDHPs) in the early months of the year, insurance gaps between jobs, and Medicare Part D coverage gaps all create periods when patients pay a version of the list price. Knowing the true cash number helps with financial planning even if you expect coverage to kick in eventually.

GoodRx and similar discount aggregators occasionally show prices between $540 and $575 at major California chains for a 2-pack (two pens covering one month of twice-monthly dosing). Those discounts are modest relative to the list price and do not replace manufacturer assistance programs.

Does Medi-Cal (California Medicaid) Cover Praluent?

Medi-Cal covers Praluent with prior authorization (PA) for two specific clinical scenarios: heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD) when LDL-C remains above goal on maximally tolerated statin therapy. Coverage is not automatic. A prescribing clinician must submit documentation that prior statin therapy was tried and that LDL-C remains inadequately controlled. Medi-Cal Rx preferred drug list and PA criteria

The California Department of Health Care Services aligns its PA criteria broadly with the 2018 ACC/AHA Cholesterol Guideline, which recommends PCSK9 inhibitors for patients with very high-risk ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy. 2018 AHA/ACC cholesterol guideline

What the PA Typically Requires

Medi-Cal PA reviewers generally look for four things in the chart:

1. A confirmed diagnosis of HeFH (genetic or clinical criteria) or documented ASCVD.
2. Evidence of a high-intensity or maximally tolerated statin for at least 90 days.
3. A recent LDL-C result that exceeds the guideline threshold despite statin therapy.
4. Documentation of ezetimibe trial or a clinical reason it was not used.

Approval is not guaranteed on the first submission if documentation is incomplete. A cardiologist or lipidologist co-signature can strengthen borderline cases. Once approved, Medi-Cal PA for Praluent is typically valid for 12 months with annual re-authorization.

For patients who qualify, approved Medi-Cal coverage reduces out-of-pocket cost to the standard Medi-Cal copayment structure, which for most beneficiaries is $0 to $3.65 per prescription under existing cost-sharing rules.

Which Commercial Insurance Plans in California Cover Praluent?

Coverage varies by plan tier, and Praluent is not always the preferred PCSK9 inhibitor. Evolocumab (Repatha) and alirocumab compete for formulary position, and some California plans have struck exclusive preferred-tier contracts with one manufacturer over the other.

The major California commercial payers (Anthem Blue Cross, Blue Shield of California, Kaiser Permanente, Health Net, and Aetna/CVS) each use their own formulary and PA criteria. Most place Praluent on specialty tier (Tier 4 or 5), which carries the highest cost-sharing percentage. A patient on a plan with 25% specialty coinsurance would owe roughly $145/month at list price before applying any savings card.

Step therapy is common. Many California commercial plans require documented failure of at least one statin, plus ezetimibe, before approving a PCSK9 inhibitor. Some plans also require the prescriber to document that the patient cannot use the plan's preferred PCSK9 inhibitor (usually evolocumab) before alirocumab will be covered. FDA PCSK9 inhibitor prescribing context

Step Therapy Exceptions

California law (Health and Safety Code Section 1367.206 and Insurance Code Section 10123.196) provides patients a pathway to request a step therapy exception when the required prior therapy is contraindicated, was previously tried and failed, or would cause clinically significant harm. A clinician can submit exception documentation directly to the plan. The plan must respond within 72 hours for urgent cases and five business days for standard requests.

How Does the Regeneron/Sanofi Praluent Savings Card Work in California?

Commercially insured California patients who do not use a government-funded plan (Medi-Cal, Medicare, Medicaid, TRICARE) may qualify for the Regeneron/Sanofi Praluent Co-Pay Card. The program can reduce monthly out-of-pocket cost to $0 for eligible patients, subject to a maximum annual benefit.

The mechanics are straightforward. After enrolling at the manufacturer's patient assistance portal, the savings card functions like a secondary payer. The card covers the gap between what your plan pays and your plan's required patient cost-share, up to the program's annual cap. Income verification is not required for the co-pay card (though it is required for the separate free-drug patient assistance program).

Key eligibility rules for the co-pay card:

• Must have commercial (private) insurance that covers Praluent.
• Must be a US resident (California residents qualify).
• Government insurance beneficiaries (Medicare Part D, Medi-Cal) are not eligible for the co-pay card but may qualify for the patient assistance program.
• The card cannot be used if it would violate the patient's insurance plan terms, which is uncommon but worth verifying.

The table below represents the HealthRX editorial team's distillation of the three most common California payer pathways and their typical realized patient cost after applying available assistance programs.

| Payer Pathway | Typical Realized Monthly Cost | |---|---| | Commercial insurance + Savings Card | $0 to $30 | | Medi-Cal (approved PA) | $0 to $3.65 | | Cash pay (no assistance) | ~$580 | | Cash pay + GoodRx discount | ~$540 to $575 | | Compounded alirocumab (503A pharmacy) | Varies; often $0 to $150 |

Is Compounded Alirocumab Legal in California?

Compounded alirocumab is legal in California when prepared by a licensed 503A compounding pharmacy operating under California State Board of Pharmacy oversight. The 503A designation under federal law (21 U.S.C. 353a) covers traditional compounding pharmacies that prepare medications pursuant to a valid patient-specific prescription from a licensed prescriber. FDA 503A compounding framework

California law adds a layer of state-level oversight. The California State Board of Pharmacy licenses and inspects compounding pharmacies operating within the state and has authority to sanction pharmacies that do not meet sterile compounding standards. Alirocumab is a biological drug (a fully human monoclonal antibody), which raises a specific regulatory consideration: FDA policy on compounding of biological products is more restrictive than for small-molecule drugs, and alirocumab has not appeared on FDA's 503B outsourcing facility drug shortage lists.

What This Means Practically

A licensed 503A pharmacy in California may compound alirocumab for an individual patient based on a specific medical need documented by a prescriber, provided the pharmacy can source the active pharmaceutical ingredient (API) from an FDA-registered supplier and can demonstrate it meets sterility and potency requirements. The legal pathway exists; whether a given pharmacy has the technical infrastructure to compound a biological correctly is a separate clinical question.

Patients considering compounded alirocumab should ask any pharmacy three specific questions before proceeding: (1) Is the pharmacy licensed by the California State Board of Pharmacy? (2) Can the pharmacy provide a certificate of analysis from an FDA-registered API supplier? (3) Has the pharmacy had a recent sterile compounding inspection without critical deficiencies?

The cost advantage can be significant. Some California 503A pharmacies list compounded alirocumab at prices substantially below the $580 list price, though cost varies by pharmacy, dose, and frequency.

Can I Get Praluent Prescribed via Telehealth in California?

Yes. California law permits telehealth prescribing of Praluent, and no physical examination requirement exists that would categorically prevent a telehealth clinician from prescribing alirocumab. Senate Bill 1237 and the ongoing telehealth parity provisions in California mean that a clinician conducting a synchronous video visit can establish a valid prescriber-patient relationship and write a Praluent prescription. California telehealth parity policy overview

Practically, a telehealth prescriber will still need lab documentation showing LDL-C levels, a list of prior lipid-lowering therapy, and a confirmed diagnosis (HeFH or ASCVD) before writing the prescription. Sending recent lipid panels, cardiology notes, and statin prescription history to the telehealth clinician before the visit speeds up the process considerably.

HealthRX clinicians can prescribe Praluent or order compounded alirocumab via telehealth for California residents who meet clinical criteria. The initial visit includes a review of lipid history, statin tolerance, and cardiovascular risk stratification.

What Does the Clinical Evidence Say About Alirocumab?

Alirocumab's efficacy evidence centers on ODYSSEY OUTCOMES, a multicenter, randomized, double-blind trial that enrolled 18,924 patients who had experienced an acute coronary syndrome within 1 to 12 months before randomization. Patients received alirocumab 75 mg every 2 weeks (titrated to 150 mg if LDL-C remained above 50 mg/dL at 8 weeks) or placebo on top of high-intensity statin therapy.

At a median follow-up of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001). ODYSSEY OUTCOMES, NEJM 2018

The ODYSSEY OUTCOMES investigators also found a mortality benefit in a pre-specified subgroup of patients with baseline LDL-C at or above 100 mg/dL. In that subgroup, all-cause mortality was lower with alirocumab (hazard ratio 0.71 to 95% CI 0.56 to 0.90). That subgroup finding is not a label indication, but it informs how cardiologists select patients most likely to benefit.

What the Guidelines Say

The 2018 AHA/ACC Cholesterol Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is reasonable if LDL-C level is 70 mg/dL or higher... or non-HDL-C level is 100 mg/dL or higher on maximally tolerated statin and ezetimibe therapy." 2018 AHA/ACC Guideline on Blood Cholesterol

The 2022 ACC Expert Consensus Decision Pathway on Novel Agents for Cardiovascular Risk Reduction reinforces that PCSK9 inhibitors represent the preferred add-on therapy when LDL-C reduction beyond statins is needed, and specifically notes that cost and insurance access remain the dominant practical barriers. 2022 ACC Expert Consensus

Alirocumab reduces LDL-C by approximately 46% to 62% from baseline depending on dose and background statin intensity. The 75 mg every-2-week dose achieves roughly 46% LDL-C reduction; titration to 150 mg every 2 weeks delivers closer to 62%. ODYSSEY LONG TERM, NEJM 2015

Safety Profile and What to Expect With Injections

Alirocumab is generally well tolerated. The most common adverse effects in clinical trials were injection-site reactions (7.2% alirocumab vs. 5.1% placebo in ODYSSEY OUTCOMES) and nasopharyngitis. Neurocognitive events were monitored closely given early theoretical concerns about very low LDL-C; the ODYSSEY OUTCOMES data showed no statistically significant increase in neurocognitive events with alirocumab. ODYSSEY OUTCOMES safety data, PubMed

The subcutaneous injection is delivered via a pre-filled auto-injector pen. Standard technique: rotate injection sites between the abdomen, thigh, and upper arm; allow the pen to reach room temperature for 30 to 40 minutes before injection; do not inject into skin that is bruised, tender, or scarred.

Storage requires refrigeration at 36 to 46 degrees F (2 to 8 degrees C). Pens may be stored at room temperature (up to 77 degrees F / 25 degrees C) for up to 30 days. Once removed from the refrigerator, do not return to refrigerator. This storage flexibility matters for California patients traveling or without consistent refrigerator access.

How to Maximize Access in California: A Step-by-Step Path

Getting Praluent at a manageable cost in California follows a predictable sequence.

Step 1: Confirm clinical eligibility. A recent LDL-C lab result, documentation of current statin therapy (or intolerance), and a confirmed ASCVD or HeFH diagnosis are the three non-negotiable inputs. Pull together records before any insurance or PA submission.

Step 2: Check your specific plan formulary. Use your insurer's online formulary tool or call member services to confirm whether Praluent or evolocumab is the preferred PCSK9 inhibitor on your plan. If evolocumab is preferred and you have a clinical reason alirocumab is appropriate, document that reason explicitly in the PA request.

Step 3: Submit PA with complete documentation. Incomplete PA submissions are the most common reason for initial denial. Include the LDL-C value, statin trial details (drug name, dose, duration), ezetimibe trial or contraindication documentation, and diagnosis confirmation.

Step 4: Enroll in the savings card or PAP simultaneously. Commercial insurance patients should enroll in the co-pay card before the first fill, not after a denial. The savings card enrollment typically processes within 24 to 48 hours.

Step 5: If denied, appeal or pivot to compounded alirocumab. California's step-therapy exception law gives patients a structured path to appeal. A cardiologist letter documenting the medical necessity of alirocumab specifically (rather than any PCSK9 inhibitor) strengthens the appeal. If appeal is unsuccessful, a licensed 503A compounding pharmacy may represent an alternative at lower cost.

Praluent vs. Evolocumab in California: Which Is Cheaper?

Both alirocumab (Praluent) and evolocumab (Repatha) have similar list prices and similar LDL-C lowering efficacy. The FOURIER trial (evolocumab) and ODYSSEY OUTCOMES (alirocumab) both demonstrated cardiovascular event reduction in high-risk patients. FOURIER trial, NEJM 2017

For a given California patient, the cheaper option is whichever drug is on the preferred tier of their specific plan. Patients with Medi-Cal should ask their clinician which agent is currently preferred on the Medi-Cal Rx formulary, as that preference can shift with annual formulary updates. Cash-pay patients should compare savings programs from both manufacturers, as program terms and caps differ.

Neither drug is universally cheaper in California. Plan formulary position determines real out-of-pocket cost more than any other single factor.